‘High Dollar’ Conflicts Should Nullify FDA Advisory Panelists – Public Citizen
This article was originally published in The Tan Sheet
Executive Summary
FDA advisory committee members with large financial conflicts of interest should be recused from meetings in which these conflicts may come into play, Public Citizen recommends after conducting a study on voting patterns
You may also be interested in...
FDA Extends Conflict Disclosure Policy To All Advisory Panel Members
FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members
FDA Extends Conflict Disclosure Policy To All Advisory Panel Members
FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members
FDA Extends Conflict Disclosure Policy To All Advisory Panel Members
FDA's draft guidance on the procedure for disclosing conflicts of interest will extend the agency's disclosure policy to cover all advisory committee members